Not an an­ti-ag­ing play? Al­tos’ top sci­en­tist says they can pre­vent ag­ing in 20 years

The nar­ra­tive at the high­ly se­cre­tive and well-fund­ed Al­tos, brought to­geth­er by Rick Klaus­ner, is that it’s not an an­ti-ag­ing com­pa­ny. Klaus­ner made that clear when he spoke with End­points ear­li­er this year: “We do not view this as ei­ther an ag­ing com­pa­ny or a longevi­ty com­pa­ny.”

Rather, the goal was to build up a team of sci­en­tif­ic heavy­weights and top in­dus­try lead­ers, pair it with be­yond-sub­stan­tial lev­els of fund­ing with a cap­i­tal B — and then set the com­pa­ny loose in­to the depths of cel­lu­lar re­ju­ve­na­tion bi­ol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER